Sign in or create an account to add this stock to your watchlist.
About TRACON Pharmaceuticals (NASDAQ:TCON)
TRACON Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration (AMD), and fibrotic diseases. Its lead product candidate is TRC105, an endoglin antibody, which is in Phase III clinical trials for angiosarcoma; randomized Phase II clinical trials for renal cell carcinoma; Phase II clinical trials for gestational trophoblastic neoplasia; Phase I/II clinical trials for hepatocellular carcinoma; Phase I clinical trial for lung cancer; Phase I/II clinical trials for breast cancer; Phase II clinical trials for prostate cancer; and randomized Phase II clinical trials for wet AMD. The company's other product candidates comprise TRC102, a small molecule that is in Phase II clinical trials for mesothelioma, Phase II clinical trials for glioblastoma, Phase I clinical trial for solid tumors, Phase I/II clinical trials for solid tumors and lymphomas, as well as Phase I clinical trial for lung cancer; and TRC253, a small molecule high affinity competitive inhibitor of wild type androgen receptor (AR) and multiple AR mutant receptors that is in Phase I/II clinical trials for the treatment prostate cancer. Its preclinical development product includes TRC694, an orally bioavailable inhibitor of NF-kB inducing kinase for the treatment of patients with hematologic malignancies, including myeloma. The company has a license agreement with Ambrx, Inc. for the development and commercialization of TRC105; and Santen Pharmaceutical Co., Ltd to develop, manufacture, and commercialize DE-122 for the ophthalmology indications of TRC105, as well as strategic licensing collaboration with Janssen Pharmaceutica N.V. to develop TRC253 and TRC694. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was founded in 2004 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:TCON
CUSIPN/A
Phone858-550-0780
Debt
Debt-to-Equity Ratio0.15
Current Ratio4.24
Quick Ratio4.24
Price-To-Earnings
Trailing P/E Ratio-2.37
Forward P/E Ratio-2.18
P/E GrowthN/A
Sales & Book Value
Annual Sales$8.76 million
Price / Sales5.47
Cash FlowN/A
Price / CashN/A
Book Value$2.39 per share
Price / Book1.13
Profitability
EPS (Most Recent Fiscal Year)($1.14)
Net Income$-19,100,000.00
Net Margins-201.21%
Return on Equity-82.47%
Return on Assets-47.74%
Miscellaneous
Employees25
Outstanding Shares17,750,000
TRACON Pharmaceuticals (NASDAQ:TCON) Frequently Asked Questions
What is TRACON Pharmaceuticals' stock symbol?
TRACON Pharmaceuticals trades on the NASDAQ under the ticker symbol "TCON."
How were TRACON Pharmaceuticals' earnings last quarter?
TRACON Pharmaceuticals (NASDAQ:TCON) released its quarterly earnings data on Wednesday, May, 9th. The biopharmaceutical company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.36) by $0.10. The biopharmaceutical company earned $3 million during the quarter, compared to the consensus estimate of $3 million. TRACON Pharmaceuticals had a negative net margin of 201.21% and a negative return on equity of 82.47%. View TRACON Pharmaceuticals' Earnings History.
When is TRACON Pharmaceuticals' next earnings date?
What price target have analysts set for TCON?
2 brokers have issued 12 month target prices for TRACON Pharmaceuticals' shares. Their forecasts range from $6.00 to $8.00. On average, they anticipate TRACON Pharmaceuticals' share price to reach $7.00 in the next twelve months. View Analyst Ratings for TRACON Pharmaceuticals.
Who are some of TRACON Pharmaceuticals' key competitors?
Some companies that are related to TRACON Pharmaceuticals include Compugen (CGEN), Pluristem Therapeutics (PSTI), Eiger Biopharmaceuticals (EIGR), Aptose Biosciences (APTO), Cidara Therapeutics (CDTX), Krystal Biotech (KRYS), Aevi Genomic Medicine (GNMX), Brainstorm Cell Therapeutics (BCLI), Applied Genetic Technologies (AGTC), Genocea Biosciences (GNCA), Curis (CRIS), BioCardia (BCDA), Champions Oncology (CSBR), CytRx (CYTR) and BiondVax (BVXV).
Who are TRACON Pharmaceuticals' key executives?
TRACON Pharmaceuticals' management team includes the folowing people:
- Dr. Charles P. Theuer, CEO, Pres & Director (Age 54)
- Ms. Patricia L. Bitar, Chief Financial Officer, Treasurer and Assistant Sec. (Age 59)
- Mr. H. Casey Logan, Chief Bus. Officer (Age 46)
- Dr. Sharon Real Ph.D., Sr. VP of Product Devel. (Age 54)
- Ms. Bonne Adams M.B.A., Sr. VP of Clinical Operations (Age 41)
When did TRACON Pharmaceuticals IPO?
(TCON) raised $47 million in an IPO on Friday, January 30th 2015. The company issued 3,600,000 shares at a price of $12.00-$14.00 per share. Wells Fargo Securities and Stifel served as the underwriters for the IPO and Needham & Company and Oppenheimer were co-managers.
Has TRACON Pharmaceuticals been receiving favorable news coverage?
News articles about TCON stock have trended somewhat positive on Saturday, according to Accern Sentiment. The research firm ranks the sentiment of press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. TRACON Pharmaceuticals earned a coverage optimism score of 0.13 on Accern's scale. They also gave news headlines about the biopharmaceutical company an impact score of 46.97 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near future.
Who are TRACON Pharmaceuticals' major shareholders?
TRACON Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include PUISSANCE CROSS-BORDER OPPORTUNITIES V LLC (15.50%), NEA Management Company LLC (19.53%), Alambic Investment Management L.P. (0.52%) and X Square Capital LLC (0.45%). Company insiders that own TRACON Pharmaceuticals stock include Enterprise Associates 14 New, Peter W Sonsini, Ronald L Shazer and William R Larue. View Institutional Ownership Trends for TRACON Pharmaceuticals.
Which institutional investors are selling TRACON Pharmaceuticals stock?
Which institutional investors are buying TRACON Pharmaceuticals stock?
TCON stock was acquired by a variety of institutional investors in the last quarter, including NEA Management Company LLC and Alambic Investment Management L.P.. Company insiders that have bought TRACON Pharmaceuticals stock in the last two years include Enterprise Associates 14 New and Peter W Sonsini. View Insider Buying and Selling for TRACON Pharmaceuticals.
How do I buy shares of TRACON Pharmaceuticals?
Shares of TCON can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is TRACON Pharmaceuticals' stock price today?
One share of TCON stock can currently be purchased for approximately $2.70.
How big of a company is TRACON Pharmaceuticals?
TRACON Pharmaceuticals has a market capitalization of $48.81 million and generates $8.76 million in revenue each year. The biopharmaceutical company earns $-19,100,000.00 in net income (profit) each year or ($1.14) on an earnings per share basis. TRACON Pharmaceuticals employs 25 workers across the globe.
How can I contact TRACON Pharmaceuticals?
TRACON Pharmaceuticals' mailing address is 4350 LA JOLLA VILLAGE DRIVE SUITE 800, San Diego CA, 92122. The biopharmaceutical company can be reached via phone at 858-550-0780 or via email at [email protected]
MarketBeat Community Rating for TRACON Pharmaceuticals (TCON)
MarketBeat's community ratings are surveys of what our community members think about TRACON Pharmaceuticals and other stocks. Vote "Outperform" if you believe TCON will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TCON will underperform the S&P 500 over the long term. You may vote once every thirty days.
TRACON Pharmaceuticals (NASDAQ:TCON) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
2 Wall Street analysts have issued ratings and price targets for TRACON Pharmaceuticals in the last 12 months. Their average twelve-month price target is $7.00, suggesting that the stock has a possible upside of 159.26%. The high price target for TCON is $8.00 and the low price target for TCON is $6.00. There are currently 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 2.67 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $7.00 | $6.00 | $6.00 | $8.00 |
| Price Target Upside: | 159.26% upside | 135.29% upside | 135.29% upside | 213.73% upside |
TRACON Pharmaceuticals (NASDAQ:TCON) Consensus Price Target History
TRACON Pharmaceuticals (NASDAQ:TCON) Analyst Ratings History
Show:
(Data available from 5/26/2016 forward)
TRACON Pharmaceuticals (NASDAQ:TCON) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
TRACON Pharmaceuticals (NASDAQ TCON) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 23.30%
Institutional Ownership Percentage: 74.62%
TRACON Pharmaceuticals (NASDAQ TCON) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/27/2018 | Enterprise Associates 14 New | Major Shareholder | Buy | 707,964 | $2.70 | $1,911,502.80 | |  |
| 6/2/2017 | William R Larue | Director | Sell | 2,500 | $2.69 | $6,725.00 | 13,388 | |
| 11/29/2016 | Peter W Sonsini | Major Shareholder | Buy | 869,565 | $5.75 | $4,999,998.75 | | |
| 6/3/2016 | Ronald L Shazer | Insider | Sell | 1,003 | $7.48 | $7,502.44 | 335 | |
| 10/16/2015 | Jafco Super V3 Investment Limi | Major Shareholder | Sell | 1,500 | $9.90 | $14,850.00 | 1,497,053 | |
| 10/15/2015 | Jafco Super V3 Investment Limi | Major Shareholder | Sell | 5,300 | $10.16 | $53,848.00 | 1,498,553 | |
| 10/13/2015 | Jafco Super V3 Investment Limi | major shareholder | Sell | 3,168 | $10.01 | $31,711.68 | 1,503,853 | |
| 10/9/2015 | Jafco Super V3 Investment Limi | major shareholder | Sell | 1,448 | $10.01 | $14,494.48 | 1,503,853 | |
| 10/8/2015 | Jafco Super V3 Investment Limi | major shareholder | Sell | 21,920 | $10.10 | $221,392.00 | 1,507,021 | |
| 10/5/2015 | Jafco Super V3 Investment Limi | major shareholder | Sell | 15,100 | $10.08 | $152,208.00 | 1,528,941 | |
| 9/25/2015 | Jafco Super V3 Investment Limi | Major Shareholder | Sell | 7,600 | $12.13 | $92,188.00 | 1,544,041 | |
| 9/24/2015 | Jafco Super V3 Investment Limi | major shareholder | Sell | 22,303 | $12.99 | $289,715.97 | 1,551,641 | |
| 9/22/2015 | Jafco Super V3 Investment Limi | major shareholder | Sell | 39,426 | $14.02 | $552,752.52 | 1,573,944 | |
| 9/21/2015 | Jafco Super V3 Investment Limi | major shareholder | Sell | 18,200 | $14.48 | $263,536.00 | 1,573,944 | |
| 9/18/2015 | Charles Theuer | CEO | Sell | 10,000 | $17.34 | $173,400.00 | | |
| 9/18/2015 | H Casey Logan | insider | Sell | 5,000 | $17.34 | $86,700.00 | | |
| 9/17/2015 | Jafco Super V3 Investment Limi | major shareholder | Sell | 42,344 | $11.78 | $498,812.32 | 1,613,370 | |
| 9/14/2015 | Jafco Super V3 Investment Limi | major shareholder | Sell | 60,038 | $11.78 | $707,247.64 | 1,655,714 | |
| 9/10/2015 | Charles Theuer | CEO | Sell | 3,516 | $12.00 | $42,192.00 | | |
| 9/9/2015 | Jafco Super V3 Investment Limi | major shareholder | Sell | 12,000 | $10.71 | $128,520.00 | 1,715,752 | |
| 9/8/2015 | Jafco Super V3 Investment Limi | major shareholder | Sell | 5,700 | $10.47 | $59,679.00 | 1,715,752 | |
| 9/4/2015 | Jafco Super V3 Investment Limi | major shareholder | Sell | 6,600 | $10.48 | $69,168.00 | 1,715,752 | |
| 9/3/2015 | Jafco Super V3 Investment Limi | major shareholder | Sell | 15,300 | $10.51 | $160,803.00 | 1,740,052 | |
| 9/1/2015 | Jafco Super V3 Investment Limi | major shareholder | Sell | 14,000 | $10.42 | $145,880.00 | 1,755,352 | |
| 8/24/2015 | Jafco Super V3 Investment Limi | Major Shareholder | Sell | 3,000 | $11.00 | $33,000.00 | 1,769,352 | |
| 8/20/2015 | Jafco Super V3 Investment Limi | major shareholder | Sell | 10,683 | $11.36 | $121,358.88 | 1,772,352 | |
| 8/18/2015 | Jafco Super V3 Investment Limi | Major Shareholder | Sell | 11,174 | $11.71 | $130,847.54 | | |
| 8/13/2015 | Jafco Super V3 Investment Limi | Major Shareholder | Sell | 9,361 | $11.60 | $108,587.60 | | |
| 2/4/2015 | M James Barrett | Major Shareholder | Buy | 500,000 | $10.00 | $5,000,000.00 | | |
(Data available from 1/1/2013 forward)
TRACON Pharmaceuticals (NASDAQ TCON) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Financial Review: Acorda Therapeutics (ACOR) versus TRACON Pharmaceuticals (TCON)
www.americanbankingnews.com - May 26 at 1:27 PM |
| TRACON Pharmaceuticals Expected to Post Q2 2018 Earnings of ($0.29) Per Share (TCON)
www.americanbankingnews.com - May 18 at 7:30 AM |
| Needham & Company LLC Lowers TRACON Pharmaceuticals (TCON) Price Target to $8.00
www.americanbankingnews.com - May 10 at 7:05 PM |
 | Edited Transcript of TCON earnings conference call or presentation 9-May-18 8:30pm GMT
finance.yahoo.com - May 10 at 5:55 PM |
| TRACON Pharmaceuticals (TCON) Releases Earnings Results, Misses Estimates By $0.10 EPS
www.americanbankingnews.com - May 10 at 4:46 PM |
 | TRACON Pharmaceuticals' (TCON) CEO Charles Theuer on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 10 at 8:26 AM |
| Tracon: 1Q Earnings Snapshot
finance.yahoo.com - May 10 at 8:26 AM |
| TRACON Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update
finance.yahoo.com - May 9 at 5:33 PM |
| Comparing Heska (HSKA) and TRACON Pharmaceuticals (TCON)
www.americanbankingnews.com - May 7 at 3:56 PM |
| TRACON to Report First Quarter 2018 Company Highlights and Financial Results on May 9, 2018
finance.yahoo.com - May 2 at 5:35 PM |
| TRACON Pharmaceuticals (TCON) Upgraded at ValuEngine
www.americanbankingnews.com - May 2 at 4:20 PM |
| TRACON Pharmaceuticals (TCON) Set to Announce Quarterly Earnings on Tuesday
www.americanbankingnews.com - May 1 at 6:40 AM |
| TRACON Pharmaceuticals (TCON) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - April 18 at 3:33 PM |
 | TRACON Pharmaceuticals Announces Closing of Previously Announced Private Placement and Appointment of Ted ...
globenewswire.com - April 10 at 5:29 PM |
| TRACON Pharmaceuticals Announces Closing of Previously Announced Private Placement and Appointment of Ted Wang, Ph.D., of Puissance Capital Management, to Board of Directors
finance.yahoo.com - April 9 at 8:19 AM |
 | Oncternal Therapeutics Further Strengthens Leadership with Additions to Board of Directors
www.prnewswire.com - April 4 at 4:12 PM |
| Edited Transcript of TCON earnings conference call or presentation 28-Feb-18 9:30pm GMT
finance.yahoo.com - April 1 at 8:22 AM |
| TRACON Pharmaceuticals Inc (TCON) Major Shareholder Enterprise Associates 14 New Buys 707,964 Shares
www.americanbankingnews.com - March 27 at 10:14 PM |
 | TRACON Pharmaceutical (TCON) Announces $38.7 Million Private Placement of Common Stock and Warrants
www.streetinsider.com - March 26 at 8:24 AM |
| TRACON Pharma secures $38.7M capital raise; shares off 5%
seekingalpha.com - March 24 at 5:14 PM |
| TRACON Pharmaceuticals Announces $38.7 Million Private Placement - GlobeNewswire (press release)
globenewswire.com - March 24 at 8:50 AM |
| TRACON Pharmaceuticals Announces $38.7 Million Private Placement
finance.yahoo.com - March 23 at 5:41 PM |
| TRACON Pharmaceuticals to Present at the 17th Annual Needham Healthcare Conference
finance.yahoo.com - March 21 at 5:37 PM |
| TRACON Pharmaceuticals to Present at 30th Annual ROTH ... - GlobeNewswire (press release)
globenewswire.com - March 7 at 8:19 AM |
| TRACON Pharmaceuticals to Present at 30th Annual ROTH Conference - GlobeNewswire (press release)
www.globenewswire.com - March 7 at 8:19 AM |
| TRACON Pharmaceuticals to Present at 30th Annual ROTH Conference
finance.yahoo.com - March 6 at 5:40 PM |
| TRACON Pharmaceuticals Inc (TCON) to Post FY2018 Earnings of $0.75 Per Share, Jefferies Group Forecasts
www.americanbankingnews.com - March 5 at 4:46 AM |
| TRACON Pharmaceuticals (TCON) Posts Earnings Results, Beats Expectations By $0.09 EPS
www.americanbankingnews.com - March 1 at 11:18 AM |
| Tracon Pharmaceuticals' (TCON) CEO Charles Theuer on Q4 2017 ... - Seeking Alpha
seekingalpha.com - March 1 at 8:16 AM |
| TRACON Pharmaceuticals Q4 Earnings Preview
finance.yahoo.com - February 28 at 6:03 PM |
| TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - February 28 at 6:03 PM |
| Analysts Expect Breakeven On The Horizon For TRACON Pharmaceuticals Inc (NASDAQ:TCON)
finance.yahoo.com - February 28 at 8:18 AM |
| Did TRACON Pharmaceuticals Inc’s (NASDAQ:TCON) Recent Earnings Growth Beat The Trend?
finance.yahoo.com - February 26 at 8:18 AM |
| $710,000.00 in Sales Expected for TRACON Pharmaceuticals Inc (TCON) This Quarter
www.americanbankingnews.com - February 23 at 2:32 PM |
| TRACON to Report Fourth Quarter and Full Year 2017 Company Highlights and Financial Results on February 28, 2018
finance.yahoo.com - February 21 at 5:26 PM |
| Brokerages Expect TRACON Pharmaceuticals Inc (TCON) to Announce -$0.45 EPS
www.americanbankingnews.com - February 21 at 3:16 AM |
| TRACON Pharmaceuticals (TCON) Scheduled to Post Earnings on Monday
www.americanbankingnews.com - February 19 at 4:44 AM |
| Analysts Anticipate TRACON Pharmaceuticals Inc (TCON) Will Post Quarterly Sales of $710,000.00
www.americanbankingnews.com - February 6 at 10:12 AM |
| TRACON Pharmaceuticals Inc (TCON) Expected to Announce Earnings of -$0.45 Per Share
www.americanbankingnews.com - February 4 at 3:18 AM |
| TRACON Pharmaceuticals Announces Positive Data from Ongoing Phase 1b/2 Trial of TRC105 in Hepatocellular Carcinoma Patients
finance.yahoo.com - January 19 at 3:44 PM |
| TRACON Pharmaceuticals Reports Granting of Inducement Awards
finance.yahoo.com - January 18 at 6:17 PM |
| Brokerages Expect TRACON Pharmaceuticals Inc (TCON) Will Announce Earnings of -$0.45 Per Share
www.americanbankingnews.com - January 18 at 5:08 AM |
| Financial Analysis: TRACON Pharmaceuticals (TCON) & Its Peers
www.americanbankingnews.com - January 11 at 8:18 AM |
| TRACON Pharmaceuticals (TCON) Downgraded by Zacks Investment Research
www.americanbankingnews.com - January 5 at 12:32 PM |
| Critical Survey: TRACON Pharmaceuticals (TCON) vs. Its Rivals
www.americanbankingnews.com - January 3 at 10:14 AM |
| ETFs with exposure to TRACON Pharmaceuticals, Inc. : December 27, 2017
finance.yahoo.com - December 27 at 1:07 PM |
| TRACON Pharmaceuticals, Inc. :TCON-US: Earnings Analysis: Q3, 2017 By the Numbers : December 26, 2017
finance.yahoo.com - December 26 at 12:44 PM |
 | Ambrx and TRACON Pharmaceuticals Announce Development and Commercialization Agreement for TRC105 in China
www.bizjournals.com - December 21 at 3:39 PM |
| TRACON Pharmaceuticals and Ambrx Announce Development and ... - GlobeNewswire (press release)
www.globenewswire.com - December 21 at 11:32 AM |
 | 35 Stocks Moving In Thursday's Pre-Market Session - Benzinga
www.benzinga.com - December 21 at 11:32 AM |
TRACON Pharmaceuticals (NASDAQ:TCON) SEC Filings
This page is loading this company's SEC Filings. Please wait...
TRACON Pharmaceuticals (NASDAQ:TCON) Income Statement, Balance Sheet and Cash Flow Statement
TRACON Pharmaceuticals (NASDAQ TCON) Stock Chart for Saturday, May, 26, 2018
Loading chart…
